Mirikizumab Disease Interactions

Mirikizumab may increase the risk of infection. Patients should be evaluated for active infection before and during treatment with mirikizumab, and administration should be avoided if infection is detected.

Mirikizumab can cause increased levels of liver enzymes and bilirubin. The effect of moderate to severe hepatic impairment on the pharmacokinetics of mirikizumab has not been evaluated. Other treatment options should be considered in patients with evidence of liver cirrhosis.

Patients treated with mirikizumab may be at increased risk for tuberculosis. Patients should be evaluated for TB before treatment with mirikizumab and therapy should be avoided in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.